Update: Upcoming and Recruiting Hepatitis C Clinical Trials

Greetings everyone, on the blog today is a collection of recruiting and upcoming hepatitis C clinical trials, as always the HCV clinical trials in this post are not a complete list; to find out if a study is enrolling patients in your area, please click here, or here for hepatitis trials listed by state.

As a point of reference a few links have been provided offering interim results from ongoing hepatitis C clinical trials presented last month at The International Liver Congress 2016.  Both the articles and clinical trials have been indexed by pharmaceutical company, click here for additional conference coverage.

The International Liver Congress 2016

AbbVie 
Genotype 1b
AbbVie - Viekirax (ombitasvir/parataprevir/ritonavir, and Exviera (dasabuvir)
By Healio *Video
Real-world experience with 3-D regimen lives up to phase 3 studies
BARCELONA — In this video perspective from the International Liver Congress 2016, Heiner Wedemeyer, MD, research group leader, department of gastroenterology, hepatology and endocrinology at Hannover Medical School in Germany, discusses his real-world experience with the German Hepatitis C-Registry. Specifically, Wedemeyer looked at the impact of Viekirax (ombitasvir/parataprevir/ritonavir, AbbVie) and Exviera (dasabuvir, AbbVie), together known as Viekira Pak in the United States, in his own practice, showing that the everyday impact is similar to that seen in phase 3 trials.

Genotype 1
ABT-493 and ABT-530 - AbbVie's Press Release
AbbVie's Investigational Regimen ABT-493 and ABT-530 Shows High SVR In HCV Genotype 1 Patients Who Failed Previous Therapy- 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with and without RBV in GT1 chronic HCV infected patients without cirrhosis who failed previous therapy with DAAs in a modified intent-to-treat analysis- 91 percent achieved SVR12 with RBV in the primary intent-to-treat analysis; 86 percent achieved SVR12 without RBV -

Genotype 3
ABT-493 and ABT-530 - The International Liver Congress 2016 Press Release
Phase 2 data show treatment efficacy in ‘difficult-to-cure’ Hepatitis C patientsABT-493 and ABT-530 - Investigational oral combination hepatitis C (HCV) treatment gets 1 step closer to offering HCV genotype 3 patients an effective therapeutic option

Genotypes 1-6
ABT-493 and ABT-530 - AbbVie's Press Release
AbbVie ABT-493 and ABT-530 For Genotypes 1-6: New Phase 2 Data Presented At The International Liver Congress- 97-98 percent SVR12 achieved with eight weeks of ABT-493 and ABT-530 in genotypes 1-3 hepatitis C virus patients without cirrhosis in SURVEYOR-1 and 2 studies(1,2)- 100 percent SVR12 achieved with 12 weeks of treatment in difficult-to-treat genotype 3 patients with compensated cirrhosis (Child-Pugh A) new to therapy (3)- 100 percent SVR12 achieved with 12 weeks of treatment in genotypes 4-6 patients without cirrhosis; eight-week duration investigated in this ongoing study (4)

Gilead
Genotype 1-6
Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857 - Gilead's Press Release
Gilead's Sofosbuvir/Velpatasvir and SOF/VEL Plus GS-9857 at The International Liver CongressTM– Studies Highlight Progress with Approved Therapies and Investigational Pangenotypic Regimens, Including Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857

Genotype 1-6
Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857 -
The International Liver Congress 2016 Press Release
High sustained virologic response achieved with sofosbuvir/velpatasvir and GS-9857, even in patients unsuccessfuly treated with direct-acting antivirals

The study showed that 99% of patients with HCV genotype 1, 2, 3, 4 and 6 who had previously received treatment, achieved SVR 12 weeks after treatment using this triple combination.
Genotype 1-6
Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857 -
Reported by Liz Highleyman
Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients

Adolescents Ledipasvir and sofosbuvir -
The International Liver Congress 2016 Press Release
Ledipasvir and sofosbuvir: Efficacy of all-oral treatment regimens in adolescents with Hepatitis C virus infectionResults from this study showed that of the 100 patients enrolled, 97% achieved SVR12 (n=97); the 3 patients who did not achieve SVR12 were lost to follow-up. No serious adverse events were reported, and the most common adverse events (reported by ≥10% of subjects) were headache (27%), diarrhoea (14%), fatigue (13%), nausea (12%), cough (10%) and vomiting (10%).

Merck
Healio Video
Zepatier shows high efficacy in hard-to-treat HCV populations

In the Head-to-Head trial, researchers randomly assigned 255 patients with HCV genotypes 1a, 1b and 4 to receive either a regimen of Zepatier (elbasvir/grazoprevir, Merck; n = 129) or Sovaldi (sofosbuvir, Gilead Sciences) with pegylated interferon alpha 2b and ribavirin (n = 126) for 12 weeks. One-quarter of the patients were treatment-experienced, 17% had compensated cirrhosis and 82% had HCV genotype 1b.
 
All patients completed the study and are currently in follow-up. Preliminary results at 4 weeks of follow-up show SVR rates of 99.2% in patients treated with elbasvir/grazoprevir and 89.7% in patients treated with sofosbuvir/pegylated interferon alpha 2b/ribavirin.

Genotypes 1 or 4
C-EDGE Head-to-Head trial Elbasvir and grazoprevir  - Merck's Press Release
Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Results From C-EDGE Head-to-Head Study in Patients with Chronic Hepatitis C Genotypes 1 or 4 Infection Presented at The International Liver Congress™ 2016

Upcoming and Recruiting Hepatitis C Clinical Trials

AbbVie
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
‎Monday, ‎April ‎11, ‎2016, ‏‎12:00:00 PM
Conditions: Hepatitis C Virus Infection; Human Immunodeficiency Virus Infection; Chronic Hepatitis C; Compensated Cirrhosis and Non-cirrhotics
Intervention: Drug: ABT-493/ABT-530
Sponsor: AbbVie
Not yet recruiting - verified April 2016

Contacts
Contact: Barbara Cristofanelli +39 06-92892-3201 barbara.cristofanelli@abbvie.com
Contact: Meredith McDonald 847-937-4453 meredith.mcdonald@abbvie.com

Locations
United States, California
Site Reference ID/Investigator# 149218 Not yet recruiting
Los Angeles, California, United States, 90036
Principal Investigator: Site Reference ID/Investigator# 149218, MD
United States, Maryland
Site Reference ID/Investigator# 149225 Not yet recruiting
Balitmore, Maryland, United States, 21287
Principal Investigator: Site Reference ID/Investigator# 149225, MD
United States, Texas
Site Reference ID/Investigator# 150791 Not yet recruiting
Houston, Texas, United States, 77004
Principal Investigator: Site Reference ID/Investigator# 150791, MD
United States, Virginia
Site Reference ID/Investigator# 149199 Not yet recruiting
Lynchburg, Virginia, United States, 24501
Principal Investigator: Site Reference ID/Investigator# 149199, MD
__________________________________________________

AbbVie
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
‎Tuesday, ‎February ‎23, ‎2016, ‏‎12:00:00 PM
Conditions: Chronic Hepatitis C; HCV; Hepatitis C Virus
Intervention: Drug: ABT-493/ABT-530
Sponsor: AbbVie
Recruiting - verified April 2016

Locations
United States, California
Site Reference ID/Investigator# 149550 Not yet recruiting
San Francisco, California, United States, 94143
Principal Investigator: Site Reference ID/Investigator# 149550, MD
United States, Indiana
Site Reference ID/Investigator# 149087 Not yet recruiting
Indianapolis, Indiana, United States, 46202-5121
Principal Investigator: Site Reference ID/Investigator# 149087, MD
United States, Utah
Site Reference ID/Investigator# 149090 Not yet recruiting
Murray, Utah, United States, 84107
Principal Investigator: Site Reference ID/Investigator# 149090, MD
Australia
Site Reference ID/Investigator# 149172 Not yet recruiting
Camperdown, Australia, 2050
Principal Investigator: Site Reference ID/Investigator# 149172, MD
Canada
Site Reference ID/Investigator# 149074 Not yet recruiting
Edmonton, Canada, T6G 2X8
Principal Investigator: Site Reference ID/Investigator# 149074, MD
Site Reference ID/Investigator# 149075 Not yet recruiting
Toronto, Canada, M5G 2N2
Principal Investigator: Site Reference ID/Investigator# 149075, MD
New Zealand
Site Reference ID/Investigator# 149173 Not yet recruiting
Auckland, New Zealand, 1142
Principal Investigator: Site Reference ID/Investigator# 149173, MD
Puerto Rico
Site Reference ID/Investigator# 149083 Recruiting
Ponce, Puerto Rico, 00716
Principal Investigator: Site Reference ID/Investigator# 149083, MD
United Kingdom
Site Reference ID/Investigator# 149157 Not yet recruiting
Edgbaston, Birmingham, United Kingdom, B15 2TH
Principal Investigator: Site Reference ID/Investigator# 149157, MD
Site Reference ID/Investigator# 149156 Not yet recruiting
London, United Kingdom, SE5 9RS
Principal Investigator: Site Reference ID/Investigator# 149156, MD

__________________________________________________

AbbVie
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
‎Monday, ‎December ‎28, ‎2015, ‏‎12:00:00 PM
Conditions: Hepatitis C Virus Infection; Chronic Hepatitis C; Compensated Cirrhosis
Intervention: Drug: ABT-493/ABT-530
Sponsor: AbbVie
Recruiting - verified April 2016

Locations
United States, California
Site Reference ID/Investigator# 149795 Recruiting
Bakersfield, California, United States, 93301
Principal Investigator: Site Reference ID/Investigator# 149795, MD
Site Reference ID/Investigator# 143509 Not yet recruiting
San Diego, California, United States, 92105
Principal Investigator: Site Reference ID/Investigator# 143509, MD
Site Reference ID/Investigator# 144079 Recruiting
San Jose, California, United States, 95128
Principal Investigator: Site Reference ID/Investigator# 144079, MD
United States, Florida
Site Reference ID/Investigator# 144858 Recruiting
Fort Pierce, Florida, United States, 34982
Principal Investigator: Site Reference ID/Investigator# 144858, MD
Site Reference ID/Investigator# 143508 Recruiting
Gainesville, Florida, United States, 32610-0272
Principal Investigator: Site Reference ID/Investigator# 143508, MD
United States, Louisiana
Site Reference ID/Investigator# 148923 Recruiting
Shreveport, Louisiana, United States, 71061
Principal Investigator: Site Reference ID/Investigator# 148923, MD
United States, New Mexico
Site Reference ID/Investigator# 143463 Recruiting
Albuquerque, New Mexico, United States, 87131-5041
Principal Investigator: Site Reference ID/Investigator# 143463, MD
United States, New York
Site Reference ID/Investigator# 143478 Recruiting
Manhasset, New York, United States, 11030
Principal Investigator: Site Reference ID/Investigator# 143478, MD
United States, North Carolina
Site Reference ID/Investigator# 144121 Recruiting
Chapel Hill, North Carolina, United States, 27599-7584
Principal Investigator: Site Reference ID/Investigator# 144121, MD
Site Reference ID/Investigator# 143409 Recruiting
Charlotte, North Carolina, United States, 28204
Principal Investigator: Site Reference ID/Investigator# 143409, MD
United States, Oregon
Site Reference ID/Investigator# 143381 Recruiting
Portland, Oregon, United States, 97210
Principal Investigator: Site Reference ID/Investigator# 143381, MD
United States, Rhode Island
Site Reference ID/Investigator# 143356 Recruiting
Providence, Rhode Island, United States, 02905
Principal Investigator: Site Reference ID/Investigator# 143356, MD
United States, Texas
Site Reference ID/Investigator# 149796 Recruiting
Arlington, Texas, United States, 76012
Principal Investigator: Site Reference ID/Investigator# 149796, MD
United States, Washington
Site Reference ID/Investigator# 143360 Recruiting
Seattle, Washington, United States, 98101
Principal Investigator: Site Reference ID/Investigator# 143360, MD
Belgium
Site Reference ID/Investigator# 143290 Recruiting
Antwerp, Belgium, 2060
Principal Investigator: Site Reference ID/Investigator# 143290, MD
Site Reference ID/Investigator# 143309 Recruiting
Brussels, Belgium, 1000
Principal Investigator: Site Reference ID/Investigator# 143309, MD
Site Reference ID/Investigator# 143307 Recruiting
Bruxelles, Belgium, 1200
Principal Investigator: Site Reference ID/Investigator# 143307, MD
Site Reference ID/Investigator# 143306 Recruiting
Edegem, Belgium, 2650
Principal Investigator: Site Reference ID/Investigator# 143306, MD
Site Reference ID/Investigator# 143310 Recruiting
Leuven, Belgium, 3000
Principal Investigator: Site Reference ID/Investigator# 143310, MD
Canada
Site Reference ID/Investigator# 143339 Recruiting
Calgary, Canada, T2N 4Z6
Principal Investigator: Site Reference ID/Investigator# 143339, MD
Site Reference ID/Investigator# 143451 Recruiting
Toronto, Canada, M5G 2C4
Principal Investigator: Site Reference ID/Investigator# 143451, MD
Site Reference ID/Investigator# 143329 Withdrawn
Toronto, Canada, M5T 2S8
Site Reference ID/Investigator# 143328 Recruiting
Toronto, Canada, M6H 3M1
Principal Investigator: Site Reference ID/Investigator# 143328, MD
Site Reference ID/Investigator# 143338 Recruiting
Winnipeg, Canada, A3E 3P4
Principal Investigator: Site Reference ID/Investigator# 143338, MD
Germany
Site Reference ID/Investigator# 148970 Recruiting
Berlin, Germany, 13353
Principal Investigator: Site Reference ID/Investigator# 148970, MD
Site Reference ID/Investigator# 144284 Recruiting
Frankfurt, Germany, 60590
Principal Investigator: Site Reference ID/Investigator# 144284, MD
Site Reference ID/Investigator# 144282 Recruiting
Kiel, Germany, 24146
Principal Investigator: Site Reference ID/Investigator# 144282, PD
Site Reference ID/Investigator# 144283 Recruiting
Mainz, Germany, 55131
Principal Investigator: Site Reference ID/Investigator# 144283, MD
Site Reference ID/Investigator# 144281 Recruiting
Muenster, Germany, 48143
Principal Investigator: Site Reference ID/Investigator# 144281, MD
South Africa
Site Reference ID/Investigator# 144432 Not yet recruiting
Cape Town, South Africa, 7925
Principal Investigator: Site Reference ID/Investigator# 144432, MD
Site Reference ID/Investigator# 144434 Not yet recruiting
Diepkloof Soweto, South Africa, 1804
Principal Investigator: Site Reference ID/Investigator# 144434, MD
Site Reference ID/Investigator# 144433 Not yet recruiting
Parktown, South Africa, 2193
Principal Investigator: Site Reference ID/Investigator# 144433, MD
Spain
Site Reference ID/Investigator# 148565 Recruiting
Barcelona, Spain, 08028
Principal Investigator: Site Reference ID/Investigator# 148565, MD
Site Reference ID/Investigator# 143849 Recruiting
Barcelona, Spain, 08916
Principal Investigator: Site Reference ID/Investigator# 143849, MD
Site Reference ID/Investigator# 143848 Recruiting
Madrid (Espana), Spain, 28007
Principal Investigator: Site Reference ID/Investigator# 143848, MD
Site Reference ID/Investigator# 143851 Recruiting
Santander, Spain, 39008
Principal Investigator: Site Reference ID/Investigator# 143851, MD
Site Reference ID/Investigator# 143847 Recruiting
Valencia, Spain, 46010
Principal Investigator: Site Reference ID/Investigator# 143847, MD

__________________________________________________

AbbVie
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
‎Tuesday, ‎December ‎22, ‎2015, ‏‎12:00:00 PM
Conditions: Chronic Hepatitis C; Hepatitis C Virus; Genotype 3 Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530; Drug: sofosbuvir; Drug: daclatasvir; Drug: daclatasvir
Sponsor: AbbVie
Recruiting - verified April 2016

Locations
United States, Alabama
Site Reference ID/Investigator# 140145 Recruiting
Birmingham, Alabama, United States, 35215
Principal Investigator: Site Reference ID/Investigator# 140145, MD
United States, Arizona
Site Reference ID/Investigator# 140167 Recruiting
Phoenix, Arizona, United States, 85054
Principal Investigator: Site Reference ID/Investigator# 140167, MD
United States, California
Site Reference ID/Investigator# 140001 Recruiting
Bakersfield, California, United States, 93301
Principal Investigator: Site Reference ID/Investigator# 140001, MD
Site Reference ID/Investigator# 140066 Recruiting
Los Angeles, California, United States, 90036
Principal Investigator: Site Reference ID/Investigator# 140066, MD
Site Reference ID/Investigator# 139996 Recruiting
Los Angeles, California, United States, 90048
Principal Investigator: Site Reference ID/Investigator# 139996, MD
Site Reference ID/Investigator# 140249 Recruiting
San Diego, California, United States, 92123
Principal Investigator: Site Reference ID/Investigator# 140249, MD
Site Reference ID/Investigator# 140035 Recruiting
San Diego, California, United States, 92120
Principal Investigator: Site Reference ID/Investigator# 140035, MD
Site Reference ID/Investigator# 140107 Recruiting
San Francisco, California, United States, 94115
Principal Investigator: Site Reference ID/Investigator# 140107, MD
United States, Colorado
Site Reference ID/Investigator# 149154 Recruiting
Englewood, Colorado, United States, 80113
Principal Investigator: Site Reference ID/Investigator# 149154, MD
Site Reference ID/Investigator# 140029 Recruiting
Lakewood, Colorado, United States, 80215
Principal Investigator: Site Reference ID/Investigator# 140029, MD
United States, Florida
Site Reference ID/Investigator# 140051 Recruiting
Fort Pierce, Florida, United States, 34982
Principal Investigator: Site Reference ID/Investigator# 140051, MD
Site Reference ID/Investigator# 140233 Recruiting
Orlando, Florida, United States, 32806
Principal Investigator: Site Reference ID/Investigator# 140233, MD
Site Reference ID/Investigator# 140010 Recruiting
West Palm Beach, Florida, United States, 33401
Principal Investigator: Site Reference ID/Investigator# 140010, MD
United States, Louisiana
Site Reference ID/Investigator# 140243 Recruiting
New Orleans, Louisiana, United States, 70112
Principal Investigator: Site Reference ID/Investigator# 140243, MD
United States, Minnesota
Site Reference ID/Investigator# 140196 Recruiting
St. Paul, Minnesota, United States, 55114
Principal Investigator: Site Reference ID/Investigator# 140196, MD
United States, New Mexico
Site Reference ID/Investigator# 149153 Recruiting
Santa Fe, New Mexico, United States, 87505
Principal Investigator: Site Reference ID/Investigator# 149153, MD, MPH
United States, New York
Site Reference ID/Investigator# 140137 Recruiting
Bronx, New York, United States, 10467
Principal Investigator: Site Reference ID/Investigator# 140137, MD
Site Reference ID/Investigator# 140182 Recruiting
Poughkeepsie, New York, United States, 12601
Principal Investigator: Site Reference ID/Investigator# 140182, MD
United States, North Carolina
Site Reference ID/Investigator# 140083 Recruiting
Asheville, North Carolina, United States, 28801
Principal Investigator: Site Reference ID/Investigator# 140083, MD
Site Reference ID/Investigator# 140081 Recruiting
Charlotte, North Carolina, United States, 28207
Principal Investigator: Site Reference ID/Investigator# 140081, MD
Site Reference ID/Investigator# 140062 Recruiting
Statesville, North Carolina, United States, 28677
Principal Investigator: Site Reference ID/Investigator# 140062, MD
United States, Oregon
Site Reference ID/Investigator# 146070 Recruiting
Portland, Oregon, United States, 97225
Principal Investigator: Site Reference ID/Investigator# 146070, MD
Site Reference ID/Investigator# 140022 Recruiting
Portland, Oregon, United States, 97210
Principal Investigator: Site Reference ID/Investigator# 140022, MD
United States, Rhode Island
Site Reference ID/Investigator# 140132 Recruiting
Providence, Rhode Island, United States, 02905
Principal Investigator: Site Reference ID/Investigator# 140132, MD
Site Reference ID/Investigator# 140159 Not yet recruiting
Providence, Rhode Island, United States, 02906
Principal Investigator: Site Reference ID/Investigator# 140159, MD
United States, Tennessee
Site Reference ID/Investigator# 140086 Recruiting
Nashville, Tennessee, United States, 37211
Principal Investigator: Site Reference ID/Investigator# 140086, MD
United States, Texas
Site Reference ID/Investigator# 140184 Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Site Reference ID/Investigator# 140184, MD
Site Reference ID/Investigator# 140240 Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Site Reference ID/Investigator# 140240, MD
Site Reference ID/Investigator# 140042 Recruiting
San Antonio, Texas, United States, 78215
Principal Investigator: Site Reference ID/Investigator# 140042, MD
Australia
Site Reference ID/Investigator# 140296 Recruiting
Adelaide, Australia, 5000
Principal Investigator: Site Reference ID/Investigator# 140296, MD
Site Reference ID/Investigator# 140298 Recruiting
Brisbane, Australia, 4029
Principal Investigator: Site Reference ID/Investigator# 140298, MD
Site Reference ID/Investigator# 140299 Recruiting
Camperdown, Australia, 2050
Principal Investigator: Site Reference ID/Investigator# 140299, MD
Site Reference ID/Investigator# 140293 Recruiting
Clayton, Australia, 3168
Principal Investigator: Site Reference ID/Investigator# 140293, MD
Site Reference ID/Investigator# 140284 Recruiting
Darlinghurst, Australia, 2010
Principal Investigator: Site Reference ID/Investigator# 140284, MD
Site Reference ID/Investigator# 140283 Recruiting
Fitzroy, Melbourne, Australia, 3065
Principal Investigator: Site Reference ID/Investigator# 140283, MD
Site Reference ID/Investigator# 140300 Recruiting
Greenslopes, Australia, 4120
Principal Investigator: Site Reference ID/Investigator# 140300, MD
Site Reference ID/Investigator# 140301 Recruiting
Kingswood, Australia, 2747
Principal Investigator: Site Reference ID/Investigator# 140301, MD
Site Reference ID/Investigator# 140294 Recruiting
Melbourne, Australia, 3004
Principal Investigator: Site Reference ID/Investigator# 140294, MD
Site Reference ID/Investigator# 140295 Recruiting
Parkville, Australia, 3050
Principal Investigator: Site Reference ID/Investigator# 140295, MD
Site Reference ID/Investigator# 140286 Recruiting
Westmead, Australia, 2145
Principal Investigator: Site Reference ID/Investigator# 140286, MD
Site Reference ID/Investigator# 140290 Recruiting
Woolloongabba, Australia, 4102
Principal Investigator: Site Reference ID/Investigator# 140290, MD
Canada
Site Reference ID/Investigator# 140311 Recruiting
Montreal, Canada, H4A 3J1
Principal Investigator: Site Reference ID/Investigator# 140311, MD
Site Reference ID/Investigator# 140308 Recruiting
Toronto, Canada, M6H 3M1
Principal Investigator: Site Reference ID/Investigator# 140308, MD
Site Reference ID/Investigator# 140355 Recruiting
Vancouver, Canada, V5Z 1H2
Principal Investigator: Site Reference ID/Investigator# 140355, MD
Site Reference ID/Investigator# 140328 Recruiting
Winnipeg, Canada, A3E 3P4
Principal Investigator: Site Reference ID/Investigator# 140328, MD
France
Site Reference ID/Investigator# 140392 Recruiting
Clichy, France, 92110
Principal Investigator: Site Reference ID/Investigator# 140392, MD
Site Reference ID/Investigator# 140414 Recruiting
Paris Cedex 13, France, 75013
Principal Investigator: Site Reference ID/Investigator# 140414, MD
Site Reference ID/Investigator# 140412 Recruiting
Paris Cedex 14, France, 75679
Principal Investigator: Site Reference ID/Investigator# 140412, MD
Site Reference ID/Investigator# 147073 Recruiting
Paris, Cedex 20, France, 75970
Principal Investigator: Site Reference ID/Investigator# 147073, MD
Site Reference ID/Investigator# 140404 Recruiting
Rennes, France, 35033
Principal Investigator: Site Reference ID/Investigator# 140404, MD
Germany
Site Reference ID/Investigator# 145900 Recruiting
Berlin, Germany, 10439
Principal Investigator: Site Reference ID/Investigator# 145900, MD
Site Reference ID/Investigator# 145901 Recruiting
Duesseldorf, Germany, 40237
Principal Investigator: Site Reference ID/Investigator# 145901, MD
Site Reference ID/Investigator# 145902 Recruiting
Hamburg, Germany, 20099
Principal Investigator: Site Reference ID/Investigator# 145902, MD
New Zealand
Site Reference ID/Investigator# 140157 Recruiting
Christchurch, Canterbury, New Zealand, 8011
Principal Investigator: Site Reference ID/Investigator# 140157, MD
Site Reference ID/Investigator# 140155 Recruiting
Dunedin, New Zealand, 9016
Principal Investigator: Site Reference ID/Investigator# 140155, MD
Site Reference ID/Investigator# 140153 Recruiting
Grafton, Auckland, New Zealand, 1010
Principal Investigator: Site Reference ID/Investigator# 140153, MD
Site Reference ID/Investigator# 140158 Recruiting
Hamilton, New Zealand, 3230
Principal Investigator: Site Reference ID/Investigator# 140158, MD
Site Reference ID/Investigator# 140156 Recruiting
Newtown, Wellington, New Zealand, 6021
Principal Investigator: Site Reference ID/Investigator# 140156, MD
Russian Federation
Site Reference ID/Investigator# 140170 Not yet recruiting
Moscow, Russian Federation, 109240
Principal Investigator: Site Reference ID/Investigator# 140170, MD, PhD
Site Reference ID/Investigator# 140168 Not yet recruiting
Moscow, Russian Federation, 111123
Principal Investigator: Site Reference ID/Investigator# 140168, MD, PhD
Site Reference ID/Investigator# 140172 Not yet recruiting
Moscow, Russian Federation, 119435
Principal Investigator: Site Reference ID/Investigator# 140172, MD/PhD
Site Reference ID/Investigator# 140180 Not yet recruiting
Moscow, Russian Federation, 127473
Principal Investigator: Site Reference ID/Investigator# 140180, MD
Site Reference ID/Investigator# 140176 Not yet recruiting
Stavropol, Russian Federation, 355017
Principal Investigator: Site Reference ID/Investigator# 140176, MD
Sweden
Site Reference ID/Investigator# 143895 Recruiting
Gothenburg, Sweden, 416 85
Principal Investigator: Site Reference ID/Investigator# 143895, MD
Site Reference ID/Investigator# 143893 Recruiting
Linkoping, Sweden, SE-581 85
Principal Investigator: Site Reference ID/Investigator# 143893, MD
Site Reference ID/Investigator# 143892 Recruiting
Malmo, Sweden, SE-205 02
Principal Investigator: Site Reference ID/Investigator# 143892, MD
Site Reference ID/Investigator# 143894 Recruiting
Stockholm, Sweden, SE 141 86
Principal Investigator: Site Reference ID/Investigator# 143894, MD
Switzerland
Site Reference ID/Investigator# 144206 Recruiting
Basel, Switzerland, CH-4031
Principal Investigator: Site Reference ID/Investigator# 144206, MD
Site Reference ID/Investigator# 143896 Recruiting
Bern, Switzerland, 3010
Principal Investigator: Site Reference ID/Investigator# 143896, MD
Site Reference ID/Investigator# 143898 Recruiting
Lugano, Switzerland, 6900
Principal Investigator: Site Reference ID/Investigator# 143898, MD
Site Reference ID/Investigator# 143899 Recruiting
St. Gallen, Switzerland, CH-9007
Principal Investigator: Site Reference ID/Investigator# 143899, MD
Site Reference ID/Investigator# 144207 Recruiting
Zurich, Switzerland, 8091
Principal Investigator: Site Reference ID/Investigator# 144207, MD
United Kingdom
Site Reference ID/Investigator# 140222 Recruiting
Birmingham, United Kingdom, B15 2TH
Principal Investigator: Site Reference ID/Investigator# 140222, MD
Site Reference ID/Investigator# 140211 Recruiting
Dundee, United Kingdom, DD1 9SY
Principal Investigator: Site Reference ID/Investigator# 140211, MD
Site Reference ID/Investigator# 150905 Recruiting
Glasgow, United Kingdom, G4 0SF
Principal Investigator: Site Reference ID/Investigator# 150905, MD
Site Reference ID/Investigator# 140214 Recruiting
London, United Kingdom, E1 1BB
Principal Investigator: Site Reference ID/Investigator# 140214, MD
Site Reference ID/Investigator# 140201 Recruiting
London, United Kingdom, SE5 9RS
Principal Investigator: Site Reference ID/Investigator# 140201, MD
Site Reference ID/Investigator# 140206 Recruiting
London, United Kingdom, W2 1NY
Principal Investigator: Site Reference ID/Investigator# 140206, MD
Site Reference ID/Investigator# 140228 Recruiting
Nottingham, United Kingdom, NG7 2UH
Principal Investigator: Site Reference ID/Investigator# 140228, MD
Site Reference ID/Investigator# 140210 Recruiting
Plymouth, United Kingdom, PL6 8DH
Principal Investigator: Site Reference ID/Investigator# 140210, MD

__________________________________________________        

AbbVie
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
‎Wednesday, ‎June ‎17, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C Infection
Interventions: Drug: ombitasvir; Drug: paritaprevir; Drug: ritonavir; Drug: dasabuvir; Drug: ribavirin
Sponsor: AbbVie
Recruiting - verified April 2016

Locations
United States, California
Site Reference ID/Investigator# 136774 Recruiting
San Francisco, California, United States, 94143
Principal Investigator: Site Reference ID/Investigator# 136774, MD
United States, Colorado
Site Reference ID/Investigator# 137017 Recruiting
Aurora, Colorado, United States, 80045-7106
Principal Investigator: Site Reference ID/Investigator# 137017, MD
United States, Florida
Site Reference ID/Investigator# 136830 Recruiting
Gainesville, Florida, United States, 32610
Principal Investigator: Site Reference ID/Investigator# 136830, MD
United States, Indiana
Site Reference ID/Investigator# 137015 Not yet recruiting
Indianapolis, Indiana, United States, 46202
Principal Investigator: Site Reference ID/Investigator# 137015, MD
United States, Louisiana
Site Reference ID/Investigator# 136775 Recruiting
Shreveport, Louisiana, United States, 71061
Principal Investigator: Site Reference ID/Investigator# 136775, MD
United States, Massachusetts
Site Reference ID/Investigator# 136831 Not yet recruiting
Boston, Massachusetts, United States, 02118
Principal Investigator: Site Reference ID/Investigator# 136831, MD
Site Reference ID/Investigator# 137174 Recruiting
Boston, Massachusetts, United States, 02115
Principal Investigator: Site Reference ID/Investigator# 137174, MD
United States, New York
Site Reference ID/Investigator# 136431 Recruiting
New York, New York, United States
Principal Investigator: Site Reference ID/Investigator# 136431, MD
United States, North Carolina
Site Reference ID/Investigator# 136589 Not yet recruiting
Chapel Hill, North Carolina, United States, 27599-7596
Principal Investigator: Site Reference ID/Investigator# 136589, MD
United States, Ohio
Site Reference ID/Investigator# 136408 Not yet recruiting
Cincinnati, Ohio, United States, 45229
Principal Investigator: Site Reference ID/Investigator# 136408, MD
United States, Pennsylvania
Site Reference ID/Investigator# 137018 Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Principal Investigator: Site Reference ID/Investigator# 137018
United States, Texas
Site Reference ID/Investigator# 136590 Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Site Reference ID/Investigator# 136590, MD
United States, Washington
Site Reference ID/Investigator# 137019 Recruiting
Seattle, Washington, United States, 98105
Principal Investigator: Site Reference ID/Investigator# 137019
Canada
Site Reference ID/Investigator# 141206 Not yet recruiting
Edmonton, Canada, T6G 1C9
Principal Investigator: Site Reference ID/Investigator# 141206, MD
Puerto Rico
Site Reference ID/Investigator# 136832 Not yet recruiting
San Juan, Puerto Rico, 00912
Principal Investigator: Site Reference ID/Investigator# 136832, MD
Spain
Site Reference ID/Investigator# 137098 Not yet recruiting
Barcelona, Spain, 08036
Principal Investigator: Site Reference ID/Investigator# 137098, MD
Site Reference ID/Investigator# 137096 Not yet recruiting
Barcelona, Spain, 08950
Principal Investigator: Site Reference ID/Investigator# 137096, MD
Site Reference ID/Investigator# 137094 Not yet recruiting
Madrid, Spain, 28046
Principal Investigator: Site Reference ID/Investigator# 137094, MD
Site Reference ID/Investigator# 137097 Not yet recruiting
Valencia, Spain, 46026
Principal Investigator: Site Reference ID/Investigator# 137097, MD

__________________________________________________        

AbbVie
Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
‎Thursday, ‎November ‎13, ‎2014, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: Ombitasvir/ABT-450/r; Drug: Sofosbuvir; Drug: Ribavirin (RBV)
Sponsor: AbbVie
Recruiting - verified April 2016

Locations
United States, California
Site Reference ID/Investigator# 132435 Withdrawn
Los Angeles, California, United States, 90036
United States, Georgia
Site Reference ID/Investigator# 132434 Withdrawn
Atlanta, Georgia, United States, 30308
Australia
Site Reference ID/Investigator# 132014 Recruiting
Adelaide, Australia, 5000
Principal Investigator: Site Reference ID/Investigator# 132014, MD
Canada
Site Reference ID/Investigator# 132436 Recruiting
Edmonton, Canada, T6G 2B7
Principal Investigator: Site Reference ID/Investigator# 132436, MD
New Zealand
Site Reference ID/Investigator# 132013 Recruiting
Grafton, New Zealand, 1010
Principal Investigator: Site Reference ID/Investigator# 132013, MD
United Kingdom
Site Reference ID/Investigator# 132011 Recruiting
London, United Kingdom, E1 1BB
Principal Investigator: Site Reference ID/Investigator# 132011, MD
Site Reference ID/Investigator# 132012 Recruiting
London, United Kingdom, SE5 9RS
Principal Investigator: Site Reference ID/Investigator# 132012, MD

__________________________________________________

AbbVie
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
‎Monday, ‎October ‎19, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsors: AbbVie; IST GmbH, Germany; Cato Research
Recruiting - verified April 2016

Locations
Canada
Site Reference ID/Investigator# 145360 Recruiting
Barrie, Canada, L4M 7G1
Principal Investigator: Site Reference ID/Investigator# 145360, MD
Site Reference ID/Investigator# 144690 Recruiting
Belleville, Canada, K8N 1E6
Principal Investigator: Site Reference ID/Investigator# 144690, MD
Site Reference ID/Investigator# 144530 Recruiting
Brampton, Canada, L6R 3J7
Principal Investigator: Site Reference ID/Investigator# 144530, MD
Site Reference ID/Investigator# 144547 Recruiting
Calgary, Canada, T2N 4Z6
Principal Investigator: Site Reference ID/Investigator# 144547, MD
Site Reference ID/Investigator# 145357 Not yet recruiting
Calgery, Canada, T2N 4Z6
Principal Investigator: Site Reference ID/Investigator# 145357, MD
Site Reference ID/Investigator# 144528 Withdrawn
Edmonton, Canada, T5H 3V9
Site Reference ID/Investigator# 144674 Not yet recruiting
Fredricton, Canada, E3B 5N5
Principal Investigator: Site Reference ID/Investigator# 144674, MD
Site Reference ID/Investigator# 144529 Not yet recruiting
Halifax, Canada, B3H 1V7
Principal Investigator: Site Reference ID/Investigator# 144529, MD
Site Reference ID/Investigator# 144691 Not yet recruiting
Hamilton, Canada, L8S 4K1
Principal Investigator: Site Reference ID/Investigator# 144691, MD
Site Reference ID/Investigator# 144693 Recruiting
Moncton, Canada, E1C 6Z8
Principal Investigator: Site Reference ID/Investigator# 144693, MD
Site Reference ID/Investigator# 144539 Not yet recruiting
Montreal, Canada, H4A 3J1
Principal Investigator: Site Reference ID/Investigator# 144539, MD
Site Reference ID/Investigator# 144675 Withdrawn
Montreal, Canada, H2L 4P9
Site Reference ID/Investigator# 145372 Not yet recruiting
Montreal, Canada, H2L 4P9
Principal Investigator: Site Reference ID/Investigator# 145372, MD
Site Reference ID/Investigator# 147592 Withdrawn
Montreal, Canada, H2L 4P9
Site Reference ID/Investigator# 147593 Not yet recruiting
Montreal, Canada, H2L 5B1
Principal Investigator: Site Reference ID/Investigator# 147593, MD
Site Reference ID/Investigator# 144692 Not yet recruiting
Montreal, Canada, H3P 2V9
Principal Investigator: Site Reference ID/Investigator# 144692, MD
Site Reference ID/Investigator# 144546 Not yet recruiting
Montreal, Canada, H3T 1E2
Principal Investigator: Site Reference ID/Investigator# 144546, MD
Site Reference ID/Investigator# 145373 Withdrawn
Montreal, Canada, H1T 2M4
Site Reference ID/Investigator# 144531 Recruiting
Quebec, Canada, G1W 4R4
Principal Investigator: Site Reference ID/Investigator# 144531, MD
Site Reference ID/Investigator# 147920 Not yet recruiting
Regina, Canada, S4P 0W5
Principal Investigator: Site Reference ID/Investigator# 147920, MD
Site Reference ID/Investigator# 144684 Recruiting
Saint John, Canada, E2L4L2
Principal Investigator: Site Reference ID/Investigator# 144684, MD
Site Reference ID/Investigator# 144695 Recruiting
Saskatoon, Canada, S7K 0C3
Principal Investigator: Site Reference ID/Investigator# 144695, MD
Site Reference ID/Investigator# 144689 Recruiting
Sherbrooke, Canada, J1G 2E8
Principal Investigator: Site Reference ID/Investigator# 144689, MD
Site Reference ID/Investigator# 145371 Withdrawn
St. John, Canada, R3E 3P4
Site Reference ID/Investigator# 147919 Not yet recruiting
Toronto, Canada, M4V1P7
Principal Investigator: Site Reference ID/Investigator# 147919, MD
Site Reference ID/Investigator# 144538 Not yet recruiting
Toronto, Canada, M5G 2C4
Principal Investigator: Site Reference ID/Investigator# 144538, MD
Site Reference ID/Investigator# 144533 Withdrawn
Toronto, Canada, M5T 2S8
Site Reference ID/Investigator# 149248 Not yet recruiting
Toronto, Canada, M6A 3B2
Principal Investigator: Site Reference ID/Investigator# 149248, MD
Site Reference ID/Investigator# 144532 Recruiting
Toronto, Canada, M6H 3M1
Principal Investigator: Site Reference ID/Investigator# 144532, MD
Site Reference ID/Investigator# 144526 Recruiting
Vancouver, Canada, V5Z 1H2
Principal Investigator: Site Reference ID/Investigator# 144526, MD
Site Reference ID/Investigator# 144688 Recruiting
Vancouver, Canada, V5Z 1M9
Principal Investigator: Site Reference ID/Investigator# 144688, MD
Site Reference ID/Investigator# 144525 Recruiting
Vancouver, Canada, V6Z 2C7
Principal Investigator: Site Reference ID/Investigator# 144525, MD
Site Reference ID/Investigator# 144676 Recruiting
Vancouver, Canada, V6Z-2K5
Principal Investigator: Site Reference ID/Investigator# 144676, MD
Site Reference ID/Investigator# 149247 Not yet recruiting
Victoria, Canada, V8V 3P9
Principal Investigator: Site Reference ID/Investigator# 149247, MD
Site Reference ID/Investigator# 145359 Recruiting
Victoria, Canada, V8W 1M8
Principal Investigator: Site Reference ID/Investigator# 145359, MD
Site Reference ID/Investigator# 144527 Recruiting
Westminster, Canada, V3L 3W5
Principal Investigator: Site Reference ID/Investigator# 144527, MD
Site Reference ID/Investigator# 145370 Recruiting
Winnipeg, Canada, R3E 3P4
Principal Investigator: Site Reference ID/Investigator# 145370, MD

__________________________________________________        

AbbVie
Ottawa, Ontario, Canada
Pilot HCV DAA and Metabolism
‎Wednesday, ‎October ‎21, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Intervention: Drug: ABT450r-ABT267-ABT333 +/- Ribavirin
Sponsors: Ottawa Hospital Research Institute; AbbVie
Recruiting - verified April 2016
Locations
Canada, Ontario
The Ottawa Hospital, General Campus Recruiting
Ottawa, Ontario, Canada
Contact: Curtis Cooper, MD 613-737-8924
Principal Investigator: Curtis Cooper, MD

__________________________________________________

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
‎Thursday, ‎July ‎17, ‎2014, ‏‎12:00:00 PM
Condition: HIV Infections
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2016

Locations
United States, Alabama
Alabama CRS Recruiting
Birmingham, Alabama, United States, 35294
Contact: Karen Savage, R.N., B.S.N. 205-975-7925 kgsavage@uab.edu
United States, California
UCLA CARE Center CRS Recruiting
Los Angeles, California, United States, 90035
Contact: Arezou S. Akha, M.D., M.S. 310-557-3798 asadighi@mednet.ucla.edu
UCSD Antiviral Research Center CRS Not yet recruiting
San Diego, California, United States, 92103
Contact: Jill Kunkel, R.N. 619-543-8080 jkunkel@ucsd.edu
Ucsf Hiv/Aids Crs Not yet recruiting
San Francisco, California, United States, 94110
Contact: Jay Dwyer 415-476-4082 ext 353 jdwyer@php.ucsf.edu
Harbor-UCLA CRS Not yet recruiting
Torrance, California, United States, 90502
Contact: Mario Guerrero 424-201-3000 ext 7318 mguerrero@labiomed.org
United States, Colorado
University of Colorado Hospital CRS Not yet recruiting
Aurora, Colorado, United States, 80045
Contact: Mary Graham Ray, R.N., M.S.N. 303-724-0712 graham.ray@ucdenver.edu
United States, District of Columbia
Whitman-Walker Health CRS Recruiting
Washington, District of Columbia, United States, 20005
Contact: Kristi Kiger, R.N. 202-939-7699 kkiger@whitman-walker.org
United States, Florida
The University of Miami AIDS Clinical Research Unit (ACRU) CRS Not yet recruiting
Miami, Florida, United States, 33136
Contact: Thomas Tanner, R.N. 305-243-3838 ttanner@med.miami.edu
United States, Georgia
The Ponce de Leon Center CRS Not yet recruiting
Atlanta, Georgia, United States, 30308-2012
Contact: Ericka Patrick, M.S.N. 404-616-6313 erpatri@emory.edu
United States, Illinois
Northwestern University CRS Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Baiba Berzins, M.P.H. 312-695-5012 Baiba@northwestern.edu
Rush University CRS Recruiting
Chicago, Illinois, United States, 60612
Contact: Janice Fritsche, M.S., A.P.R.N, B.C. 312-942-4810 Janice_Fritsche@rush.edu
United States, Maryland
Johns Hopkins University CRS Recruiting
Baltimore, Maryland, United States, 21205
Contact: Ilene Wiggins, R.N. 410-614-2766 iwiggin1@jhmi.edu
United States, Massachusetts
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS Not yet recruiting
Boston, Massachusetts, United States, 02115
Contact: Cheryl E. Keenan, R.N. 617-732-5635 ckeenan2@partners.org
Massachusetts General Hospital CRS (MGH CRS) Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Theresa Flynn, R.N., M.S.N., A.N.P., B.S.N. 617-724-0072 tflynn@partners.org
United States, Missouri
Washington University Therapeutics (WT) CRS Not yet recruiting
St. Louis, Missouri, United States, 63110-1010
Contact: Michael K. Klebert, R.N.,C., Ph.D., A.N.P., BCP 314-747-1098 mklebert@dom.wustl.edu
United States, New Jersey
New Jersey Medical School Clinical Research Center CRS Recruiting
Newark, New Jersey, United States, 07103
Contact: Baljinder Singh 973-972-3811 singhba@njms.rutgers.edu
United States, New York
Columbia P&S CRS Not yet recruiting
New York, New York, United States, 10032-3732
Contact: Steven Palmer, P.A. -C 212-342-2958 sp500@cumc.columbia.edu
Weill Cornell Uptown CRS Not yet recruiting
New York, New York, United States, 10065
Contact: Valery Hughes 212-746-4393 Vah9001@med.cornell.edu
Weill Cornell Chelsea CRS Recruiting
New York, New York, United States, 10010
Contact: Todd Stroberg, R.N., B.S.N. 212-746-7198 tstrober@med.cornell.edu
University of Rochester Adult HIV Therapeutic Strategies Network CRS Not yet recruiting
Rochester, New York, United States, 14642
Contact: Emily L. Cosimano, B.S.N. 585-276-5903 Emily_Cosimano@urmc.rochester.edu
United States, North Carolina
Chapel Hill CRS Withdrawn
Chapel Hill, North Carolina, United States, 27599
Greensboro CRS Not yet recruiting
Greensboro, North Carolina, United States, 27401
Contact: Kim Epperson, R.N., B.S.N., CRC 336-832-3262 kim.epperson@conehealth.com
United States, Ohio
Cincinnati Clinical Research Site Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Sharon Kohrs, R.N., B.S.N. 513-584-6383 kohrssd@ucmail.uc.edu
Case Clinical Research Site Not yet recruiting
Cleveland, Ohio, United States, 44106
Contact: Jane Baum, R.N. 216-844-2546 jb@clevelandactu.org
Ohio State University CRS Not yet recruiting
Columbus, Ohio, United States, 43210
Contact: Kathy Watson, B.S.N. 614-293-5856 kathy.watson@osumc.edu
United States, Pennsylvania
Penn Therapeutics, CRS Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Joseph Quinn, R.N., B.S.N. 215-349-8092 joseph.quinn@uphs.upenn.edu
University of Pittsburgh CRS Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Patricia Peters, R.Ph. 412-383-1434 pep1@pitt.edu
United States, Rhode Island
The Miriam Hospital Clinical Research Site (TMH CRS) CRS Recruiting
Providence, Rhode Island, United States, 02906
Contact: Pamela Poethke, R.N. 401-793-4971 ppoethke@lifespan.org
United States, Tennessee
Vanderbilt Therapeutics (VT) CRS Not yet recruiting
Nashville, Tennessee, United States, 37204
Contact: Beverly O. Woodward, M.S.N., R.N. 615-936-8516 beverly.o.woodward@vanderbilt.edu
United States, Texas
Trinity Health and Wellness Center CRS Not yet recruiting
Dallas, Texas, United States, 75208
Contact: Holly Wise, BAAS, CCRP 972-807-7370 Holly.Wise@aidsarms.org
Houston AIDS Research Team CRS Recruiting
Houston, Texas, United States, 77030
Contact: Maria L. Martinez 713-500-6718 Maria.L.Martinez@uth.tmc.edu
United States, Washington
University of Washington AIDS CRS Recruiting
Seattle, Washington, United States, 98104-9929
Contact: Christine Jonsson 206-744-8886 cjonsson@u.washington.edu
Puerto Rico
Puerto Rico AIDS Clinical Trials Unit CRS Recruiting
San Juan, Puerto Rico, 00935
Contact: Sylvia I. Davila Nieves, M.Sc. 787-767-9192 sylvia.davila1@upr.edu

__________________________________________________

AbbVie
Greece
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
‎Thursday, ‎March ‎24, ‎2016, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Recruiting - verified April 2016
Locations
Greece
Contacts
Contact: Georgios Mitas, MS 00302144165468 georgios.mitas@abbvie.com 
Contact: Antonis Kyriakakis, BS 002144165471 antonis.kyriakakis@abbvie.com

__________________________________________________
AbbVie
Japan
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
‎Wednesday, ‎March ‎9, ‎2016, ‏‎12:00:00 PM
Conditions: Chronic Hepatitis C Virus; Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530; Drug: Ombitasvir/paritaprevir/ritonavir
Sponsor: AbbVie
Recruiting - verified April 2016
Contacts
Contact: Ryotaro Matsuzawa +81-3-4577-9467 ryotaro.matsuzawa@abbvie.com
Japan

__________________________________________________

AbbVie
Austria
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
‎Tuesday, ‎October ‎20, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Recruiting - verified April 2016
Austria

__________________________________________________

AbbVie
Ireland
The Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
‎Tuesday, ‎October ‎20, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Recruiting - verified April 2016
Ireland

__________________________________________________

AbbVie
Belgium
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
‎Monday, ‎October ‎19, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C, Genotype 1 or 4
Intervention:
Sponsors: AbbVie; IST GmbH, Germany
Recruiting - verified April 2016
Belgium

__________________________________________________

AbbVie
Russian Federation
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study
‎Thursday, ‎January ‎28, ‎2016, ‏‎12:00:00 PM
Conditions: Chronic Hepatitis C; Genotype 1
Intervention: Drug: ABBVIE REGIMEN ± RBV
Sponsor: AbbVie
Recruiting - verified April 2016
Locations
Russian Federation
__________________________________________________

AbbVie
Hungary
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS
‎Wednesday, ‎December ‎16, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsors: AbbVie; IST GmbH, Germany
Recruiting - verified April 2016
Locations
Hungary


__________________________________________________

AbbVie
Japan
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
‎Thursday, ‎December ‎10, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C Virus
Intervention:
Sponsor: AbbVie
Recruiting - verified April 2016
Locations
Japan

__________________________________________________

AbbVie
Germany
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
‎Tusday, ‎November ‎24, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Recruiting - verified April 2016
Locations
Germany

__________________________________________________

AbbVie
France
The Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in France
‎Tuesday, ‎November ‎24, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Recruiting - verified April 2016
Locations
France

__________________________________________________

Gilead Sciences
United States, Maryland
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Subjects With Previous DAA Experience
‎Monday, ‎April ‎11, ‎2016, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention: Drug: Sofosbuvir/Velpatasvir/GS-9857
Sponsors: University of Maryland; Unity Health Care, Inc.; Gilead Sciences
Recruiting - verified April 2016
Locations
United States, Maryland
Institute of Human Virology Recruiting
Baltimore, Maryland, United States, 21201
Contact: Eleanor Wilson, MD 410-706-1710 ewilson@ihv.umaryland.edu
Contact: Jennifer Hoffmann, MSN/MPH 410-706-0294 jhoffmann@ihv.umaryland.edu

__________________________________________________

Gilead Sciences
Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
‎Monday, ‎November ‎16, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/GS-9857; Drug: SOF/VEL
Sponsor: Gilead Sciences
Recruiting - verified April 2016

Locations
United States, California
Recruiting
Long Beach, California, United States
Recruiting
Los Angeles, California, United States
Recruiting
Palo Alto, California, United States
Recruiting
Pasadena, California, United States
Recruiting
Rialto, California, United States
Recruiting
San Diego, California, United States
Recruiting
San Francisco, California, United States
United States, Colorado
Recruiting
Aurora, Colorado, United States
Recruiting
Englewood, Colorado, United States
United States, District of Columbia
Recruiting
Washington, District of Columbia, United States
United States, Florida
Recruiting
Gainesville, Florida, United States
Recruiting
Miami, Florida, United States
Recruiting
Orlando, Florida, United States
Recruiting
Wellington, Florida, United States
United States, Georgia
Recruiting
Atlanta, Georgia, United States
Recruiting
Marietta, Georgia, United States
United States, Illinois
Recruiting
Chicago, Illinois, United States
United States, Indiana
Recruiting
Indianapolis, Indiana, United States
United States, Louisiana
Recruiting
Bastrop, Louisiana, United States
United States, Maryland
Recruiting
Baltimore, Maryland, United States
Recruiting
Catonsville, Maryland, United States
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States
United States, Michigan
Recruiting
Ann Arbor, Michigan, United States
Recruiting
Detroit, Michigan, United States
United States, Missouri
Recruiting
Kansas City, Missouri, United States
Recruiting
Saint Louis, Missouri, United States
United States, New Jersey
Recruiting
Hillsborough, New Jersey, United States
United States, New York
Recruiting
Bronx, New York, United States
Recruiting
Manhasset, New York, United States
Recruiting
New York, New York, United States
United States, North Carolina
Recruiting
Asheville, North Carolina, United States
Recruiting
Fayetteville, North Carolina, United States
United States, Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States
Recruiting
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Recruiting
Providence, Rhode Island, United States
United States, Tennessee
Recruiting
Germantown, Tennessee, United States
Recruiting
Knoxville, Tennessee, United States
Recruiting
Nashville, Tennessee, United States
United States, Texas
Recruiting
Houston, Texas, United States
Recruiting
Live Oak, Texas, United States
Recruiting
San Antonio, Texas, United States
United States, Utah
Recruiting
Murray, Utah, United States
United States, Virginia
Recruiting
Falls Church, Virginia, United States
Recruiting
Norfolk, Virginia, United States
Recruiting
Richmnond, Virginia, United States
Recruiting
Richmond, Virginia, United States
United States, Washington
Recruiting
Seattle, Washington, United States
United States, Wisconsin
Recruiting
Madison, Wisconsin, United States
Australia, New South Wales
Recruiting
Camperdown, New South Wales, Australia
Recruiting
Darlinghurst, New South Wales, Australia
Australia, Queensland
Recruiting
Herston, Queensland, Australia
Australia, Victoria
Recruiting
Clayton, Victoria, Australia
Recruiting
Fitzroy, Victoria, Australia
Recruiting
Melbourne, Victoria, Australia
Australia, Western Australia
Recruiting
Perth, Western Australia, Australia
Canada, Alberta
Recruiting
Calgary, Alberta, Canada
Recruiting
Edmonton, Alberta, Canada
Canada, British Columbia
Recruiting
Vancouver, British Columbia, Canada
Canada, Ontario
Recruiting
Brampton, Ontario, Canada
Recruiting
Ottawa, Ontario, Canada
Recruiting
Toronto, Ontario, Canada
Canada, Quebec
Recruiting
Montreal, Quebec, Canada
France
Recruiting
Bobigny, France
Recruiting
Clermont-Ferrand, France
Recruiting
Clichy, France
Recruiting
Creteil, France
Recruiting
Grenoble, France
Recruiting
Lille, France
Recruiting
Limoges, France
Recruiting
Lyon, France
Recruiting
Marseille, France
Recruiting
Montpellier, France
Recruiting
Nice, France
Recruiting
Paris, France
Recruiting
Pessac, France
Recruiting
Rennes, France
Recruiting
Rouen, France
Recruiting
Strasbourg, France
Recruiting
Toulouse, France
Recruiting
Vandoeuvre-les-Nancy, France
Recruiting
Villejuif, France
Germany
Recruiting
Berlin, Germany
Recruiting
Bonn, Germany
Recruiting
Frankfurt am Main, Germany
Recruiting
Hamburg, Germany
Recruiting
Köln, Germany
New Zealand
Recruiting
Christchurch, New Zealand
Recruiting
Grafton, New Zealand
Puerto Rico
Recruiting
San Juan, Puerto Rico
United Kingdom
Recruiting
London, United Kingdom
Recruiting
Manchester, United Kingdom
Recruiting
Nottingham, United Kingdom
Recruiting
Oxford, United Kingdom
Recruiting
Portsmouth, United Kingdom
__________________________________________________

Gilead Sciences
Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
‎Monday, ‎November ‎16, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/GS-9857; Drug: Placebo
Sponsor: Gilead Sciences
Recruiting - verified April 2016

Locations
United States, California
Recruiting
Long Beach, California, United States
Recruiting
Los Angeles, California, United States
Recruiting
Palo Alto, California, United States
Recruiting
Pasadena, California, United States
Recruiting
Rialto, California, United States
Recruiting
San Diego, California, United States
Recruiting
San Francisco, California, United States
United States, Colorado
Recruiting
Aurora, Colorado, United States
Recruiting
Englewood, Colorado, United States
United States, District of Columbia
Recruiting
Washington, District of Columbia, United States
United States, Florida
Recruiting
Gainesville, Florida, United States
Recruiting
Miami, Florida, United States
Recruiting
Orlando, Florida, United States
Recruiting
Wellington, Florida, United States
United States, Georgia
Recruiting
Atlanta, Georgia, United States
Recruiting
Marietta, Georgia, United States
United States, Illinois
Recruiting
Chicago, Illinois, United States
United States, Indiana
Recruiting
Indianapolis, Indiana, United States
United States, Louisiana
Recruiting
Bastrop, Louisiana, United States
United States, Maryland
Recruiting
Baltimore, Maryland, United States
Recruiting
Catonsville, Maryland, United States
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States
United States, Michigan
Recruiting
Ann Arbor, Michigan, United States
Recruiting
Detroit, Michigan, United States
United States, Missouri
Recruiting
Kansas City, Missouri, United States
Recruiting
Saint Louis, Missouri, United States
United States, New Jersey
Recruiting
Hillsborough, New Jersey, United States
United States, New York
Recruiting
Bronx, New York, United States
Recruiting
New York, New York, United States
United States, North Carolina
Recruiting
Asheville, North Carolina, United States
Recruiting
Fayetteville, North Carolina, United States
United States, Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States
Recruiting
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Recruiting
Providence, Rhode Island, United States
United States, Tennessee
Recruiting
Germantown, Tennessee, United States
Recruiting
Knoxville, Tennessee, United States
Recruiting
Nashville, Tennessee, United States
United States, Texas
Recruiting
Houston, Texas, United States
Recruiting
Live Oak, Texas, United States
Recruiting
San Antonio, Texas, United States
United States, Utah
Recruiting
Murray, Utah, United States
United States, Virginia
Recruiting
Falls Church, Virginia, United States
Recruiting
Norfolk, Virginia, United States
Recruiting
Richmond, Virginia, United States
United States, Washington
Recruiting
Seattle, Washington, United States
United States, Wisconsin
Recruiting
Madison, Wisconsin, United States
Australia, New South Wales
Recruiting
Camperdown, New South Wales, Australia
Recruiting
Darlinghurst, New South Wales, Australia
Australia, Queensland
Recruiting
Herston, Queensland, Australia
Australia, Victoria
Recruiting
Clayton, Victoria, Australia
Recruiting
Fitzroy, Victoria, Australia
Recruiting
Melbourne, Victoria, Australia
Canada
Canada, Alberta
Recruiting
Calgary, Alberta, Canada
Recruiting
Edmonton, Alberta, Canada
Canada, British Columbia
Recruiting
Vancouver, British Columbia, Canada
Canada, Ontario
Recruiting
Brampton, Ontario, Canada
Recruiting
Toronto, Ontario, Canada
Canada, Quebec
Recruiting
Montreal, Quebec, Canada
France
Recruiting
Clermont-Ferrand, France
Recruiting
Clichy, France
Recruiting
Creteil, France
Recruiting
Grenoble, France
Recruiting
Lille, France
Recruiting
Limoges, France
Recruiting
Lyon, France
Recruiting
Marseille, France
Recruiting
Montpellier, France
Recruiting
Nice, France
Recruiting
Paris, France
Recruiting
Pessac, France
Recruiting
Rennes, France
Recruiting
Rouen, France
Recruiting
Strasbourg, France
Recruiting
Toulouse, France
Recruiting
Vandoeuvre-les-Nancy, France
Recruiting
Villejuif, France
Germany
Recruiting
Berlin, Germany
Recruiting
Bonn, Germany
Recruiting
Frankfurt am Main, Germany
Recruiting
Hamburg, Germany
Recruiting
Köln, Germany
New Zealand
Recruiting
Christchurch, New Zealand
Recruiting
Grafton, New Zealand
Puerto Rico
Recruiting
San Juan, Puerto Rico
United Kingdom
Recruiting
London, United Kingdom
Recruiting
Manchester, United Kingdom
Recruiting
Nottingham, United Kingdom
Recruiting
Portsmouth, United Kingdom

_________________________________________________

Gilead Sciences
Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
‎Monday, ‎December ‎21, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/GS-9857; Drug: SOF/VEL
Sponsor: Gilead Sciences
Recruiting - verified April 2016

Locations
United States, California
Recruiting
Long Beach, California, United States
Recruiting
Los Angeles, California, United States
Recruiting
Palo Alto, California, United States
Recruiting
Rialto, California, United States
Recruiting
San Diego, California, United States
Recruiting
San Francisco, California, United States
United States, Colorado
Recruiting
Aurora, Colorado, United States
Recruiting
Englewood, Colorado, United States
United States, District of Columbia
Recruiting
Washington, District of Columbia, United States
United States, Florida
Recruiting
Gainesville, Florida, United States
Recruiting
Miami, Florida, United States
Recruiting
Orlando, Florida, United States
Recruiting
Wellington, Florida, United States
United States, Georgia
Recruiting
Atlanta, Georgia, United States
Recruiting
Marietta, Georgia, United States
United States, Illinois
Recruiting
Chicago, Illinois, United States
United States, Indiana
Recruiting
Indianapolis, Indiana, United States
United States, Louisiana
Recruiting
Bastrop, Louisiana, United States
United States, Maryland
Recruiting
Baltimore, Maryland, United States
Recruiting
Catonsville, Maryland, United States
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States
United States, Michigan
Recruiting
Ann Arbor, Michigan, United States
Recruiting
Detroit, Michigan, United States
United States, Missouri
Recruiting
Kansas City, Missouri, United States
Recruiting
Saint Louis, Missouri, United States
United States, New Jersey
Recruiting
Hillsborough, New Jersey, United States
United States, New York
Recruiting
Bronx, New York, United States
Recruiting
New York, New York, United States
United States, North Carolina
Recruiting
Asheville, North Carolina, United States
Recruiting
Fayetteville, North Carolina, United States
United States, Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States
Recruiting
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Recruiting
Providence, Rhode Island, United States
United States, Tennessee
Recruiting
Germantown, Tennessee, United States
Recruiting
Knoxville, Tennessee, United States
Recruiting
Nashville, Tennessee, United States
United States, Texas
Recruiting
Houston, Texas, United States
Recruiting
San Antonio, Texas, United States
United States, Utah
Recruiting
Murray, Utah, United States
United States, Virginia
Recruiting
Falls Church, Virginia, United States
Recruiting
Norfolk, Virginia, United States
Recruiting
Richmond, Virginia, United States
United States, Washington
Recruiting
Seattle, Washington, United States
Australia, New South Wales
Recruiting
Camperdown, New South Wales, Australia
Recruiting
Darlinghurst, New South Wales, Australia
Australia, Queensland
Recruiting
Herston, Queensland, Australia
Australia, Victoria
Recruiting
Clayton, Victoria, Australia
Recruiting
Fitzroy, Victoria, Australia
Recruiting
Melbourne, Victoria, Australia
Canada, Alberta
Recruiting
Calgary, Alberta, Canada
Recruiting
Edmonton, Alberta, Canada
Canada, British Columbia
Recruiting
Vancouver, British Columbia, Canada
Canada, Ontario
Recruiting
Brampton, Ontario, Canada
Recruiting
Toronto, Ontario, Canada
Canada, Quebec
Recruiting
Montreal, Quebec, Canada
France
Recruiting
Bobigny, France
Recruiting
Clermont-Ferrand, France
Recruiting
Clichy, France
Recruiting
Creteil, France
Recruiting
Grenoble, France
Recruiting
Lille, France
Recruiting
Limoges, France
Recruiting
Lyon, France
Recruiting
Marseille, France
Recruiting
Montpellier, France
Recruiting
Nice, France
Recruiting
Orleans, France
Recruiting
Paris, France
Recruiting
Pessac, France
Recruiting
Rennes, France
Recruiting
Rouen, France
Recruiting
Strasbourg, France
Recruiting
Toulouse, France
Recruiting
Vandoeuvre-les-Nancy, France
Recruiting
Villejuif, France
Germany
Recruiting
Berlin, Germany
Recruiting
Bonn, Germany
Recruiting
Frankfurt am Main, Germany
Recruiting
Hamburg, Germany
Recruiting
Hannover, Germany
Recruiting
Köln, Germany
New Zealand
Recruiting
Grafton, Auckland, New Zealand
Recruiting
Christchurch, New Zealand
Puerto Rico
Recruiting
San Juan, Puerto Rico
United Kingdom
Recruiting
London, United Kingdom
Recruiting
Manchester, United Kingdom
Recruiting
Nottingham, United Kingdom
Recruiting
Oxford, United Kingdom
Recruiting
Portsmouth, United Kingdom

__________________________________________________

Gilead Sciences
Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
‎Monday, ‎December ‎21, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/GS-9857; Drug: SOF/VEL
Sponsor: Gilead Sciences
Recruiting - verified April 2016

Locations
United States, California
Recruiting
Long Beach, California, United States
Recruiting
Los Angeles, California, United States
Recruiting
Palo Alto, California, United States
Recruiting
Pasadena, California, United States
Recruiting
Rialto, California, United States
Recruiting
San Diego, California, United States
Recruiting
San Francisco, California, United States
United States, Colorado
Recruiting
Aurora, Colorado, United States
Recruiting
Englewood, Colorado, United States
United States, District of Columbia
Recruiting
Washington, District of Columbia, United States
United States, Florida
Recruiting
Gainesville, Florida, United States
Recruiting
Miami, Florida, United States
Recruiting
Orlando, Florida, United States
Recruiting
Wellington, Florida, United States
United States, Georgia
Recruiting
Atlanta, Georgia, United States
Recruiting
Marietta, Georgia, United States
United States, Illinois
Recruiting
Chicago, Illinois, United States
United States, Indiana
Recruiting
Indianapolis, Indiana, United States
United States, Louisiana
Recruiting
Bastrop, Louisiana, United States
United States, Maryland
Recruiting
Baltimore, Maryland, United States
Recruiting
Catonsville, Maryland, United States
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States
United States, Michigan
Recruiting
Ann Arbor, Michigan, United States
Recruiting
Detroit, Michigan, United States
United States, Missouri
Recruiting
Kansas City, Missouri, United States
Recruiting
Saint Louis, Missouri, United States
United States, New Jersey
Recruiting
Hillsborough, New Jersey, United States
United States, New York
Recruiting
Bronx, New York, United States
Recruiting
Manhasset, New York, United States
Recruiting
New York, New York, United States
United States, North Carolina
Recruiting
Asheville, North Carolina, United States
Recruiting
Fayetteville, North Carolina, United States
United States, Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States
Recruiting
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Recruiting
Providence, Rhode Island, United States
United States, Tennessee
Recruiting
Germantown, Tennessee, United States
Recruiting
Knoxville, Tennessee, United States
Recruiting
Nashville, Tennessee, United States
United States, Texas
Recruiting
Houston, Texas, United States
Recruiting
San Antonio, Texas, United States
United States, Utah
Recruiting
Murray, Utah, United States
United States, Virginia
Recruiting
Falls Church, Virginia, United States
Recruiting
Norfolk, Virginia, United States
Recruiting
Richmond, Virginia, United States
United States, Washington
Recruiting
Seattle, Washington, United States
United States, Wisconsin
Recruiting
Madison, Wisconsin, United States
Australia, New South Wales
Recruiting
Camperdown, New South Wales, Australia
Recruiting
Darlinghurst, New South Wales, Australia
Australia, Queensland
Recruiting
Herston, Queensland, Australia
Australia, Victoria
Recruiting
Clayton, Victoria, Australia
Recruiting
Fitzroy, Victoria, Australia
Recruiting
Melbourne, Victoria, Australia
Canada, Alberta
Recruiting
Calgary, Alberta, Canada
Recruiting
Edmonton, Alberta, Canada
Canada, British Columbia
Recruiting
Vancouver, British Columbia, Canada
Canada, Ontario
Recruiting
Brampton, Ontario, Canada
Recruiting
Ottawa, Ontario, Canada
Recruiting
Toronto, Ontario, Canada
Canada, Quebec
Recruiting
Montreal, Quebec, Canada
France
Recruiting
Bobigny, France
Recruiting
Clermont-Ferrand, France
Recruiting
Clichy, France
Recruiting
Creteil, France
Recruiting
Grenoble, France
Recruiting
Lille, France
Recruiting
Limoges, France
Recruiting
Lyon, France
Recruiting
Marseille, France
Recruiting
Montpellier, France
Recruiting
Nice, France
Recruiting
Orleans, France
Recruiting
Orléans, France
Recruiting
Paris, France
Recruiting
Pessac, France
Recruiting
Rennes, France
Recruiting
Rouen, France
Recruiting
Strasbourg, France
Recruiting
Toulouse, France
Recruiting
Vandoeuvre-les-Nancy, France
Recruiting
Villejuif, France
Germany
Recruiting
Berlin, Germany
Recruiting
Bonn, Germany
Recruiting
Frankfurt am Main, Germany
Recruiting
Hamburg, Germany
Recruiting
Hannover, Germany
Recruiting
Köln, Germany
New Zealand
Recruiting
Grafton, Auckland, New Zealand
Recruiting
Christchurch, New Zealand
Puerto Rico
Recruiting
San Juan, Puerto Rico
United Kingdom
Recruiting
London, United Kingdom
Recruiting
Manchester, United Kingdom
Recruiting
Nottingham, United Kingdom
Recruiting
Oxford, United Kingdom
Recruiting
Portsmouth, United Kingdom   

__________________________________________________

Gilead Sciences
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection
‎Tuesday, ‎September ‎23, ‎2014, ‏‎12:00:00 PM
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF; Drug: Placebo to match LDV/SOF; Drug: RBV; Drug: LDV/SOF
Sponsor: Gilead Sciences
Recruiting - verified April 2016

Locations
United States, Alabama
Not yet recruiting
Birmingham, Alabama, United States
United States, Arizona
Recruiting
Phoenix, Arizona, United States
United States, California
Recruiting
Los Angeles, California, United States
Recruiting
San Francisco, California, United States
United States, Colorado
Recruiting
Aurora, Colorado, United States
United States, District of Columbia
Recruiting
Washington, District of Columbia, United States
United States, Florida
Recruiting
Gainesville, Florida, United States
United States, Georgia
Recruiting
Atlanta, Georgia, United States
United States, Indiana
Recruiting
Indianapolis, Indiana, United States
United States, Kentucky
Recruiting
Louisville, Kentucky, United States
United States, Maryland
Recruiting
Baltimore, Maryland, United States
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States
United States, Missouri
Recruiting
Saint Louis, Missouri, United States
United States, Nebraska
Recruiting
Omaha, Nebraska, United States
United States, New York
Recruiting
New York, New York, United States
United States, North Carolina
Recruiting
Chapel Hill, North Carolina, United States
United States, Ohio
Recruiting
Cincinnati, Ohio, United States
Recruiting
Columbus, Ohio, United States
United States, Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States
United States, Tennessee
Recruiting
Nashville, Tennessee, United States
United States, Texas
Recruiting
Dallas, Texas, United States
Recruiting
Fort Worth, Texas, United States
Recruiting
San Antonio, TX, Texas, United States
United States, Washington
Recruiting
Seattle, Washington, United States
United States, West Virginia
Recruiting
Morgantown, West Virginia, United States
Australia, New South Wales
Recruiting
Newcastle, New South Wales, Australia
Recruiting
Westmead, New South Wales, Australia
Australia, Victoria
Recruiting
Parkville, Victoria, Australia
New Zealand
Recruiting
Auckland, New Zealand
United Kingdom
Recruiting
Birmingham, England, United Kingdom
Recruiting
Leeds, England, United Kingdom
Recruiting
London, England, United Kingdom
Withdrawn
Nottingham, England, United Kingdom
Recruiting
Glasgow, Scotland, United Kingdom

__________________________________________________

Gilead Sciences
Japan
Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
‎Friday, ‎August ‎28, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF; Drug: COPE
Sponsors: Gilead Sciences; Chugai Pharmaceutical
Recruiting - verified April 2016

Japan

__________________________________________________

Gilead Sciences
Japan
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
‎Monday, ‎April ‎11, ‎2016, ‏‎12:00:00 PM
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF; Drug: SOF; Drug: RBV
Sponsor: Gilead Sciences
Recruiting - verified April 2016

Contacts
Contact: Gilead Study Team GS-US-337-1903@gilead.com

Locations
Japan
Recruiting
Itabashi, Japan
Recruiting
Osaka, Japan
Recruiting
Suita, Japan

__________________________________________________

Gilead Sciences
Malaysia Singapore
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
‎Friday, ‎January ‎29, ‎2016, ‏‎12:00:00 PM
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Sponsor: Gilead Sciences
Recruiting - verified April 2016
Locations

Malaysia
University of Malaya Recruiting
Kuala Lumpur, Malaysia, 59100
Singapore
National University Hospital Recruiting
Singapore, Singapore, 119074
Singapore General Hospital Not yet recruiting
Singapore, Singapore, 169608

__________________________________________________

Gilead Sciences
Taiwan
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
‎Monday, ‎November ‎23, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C Virus Infection
Intervention: Drug: LDV/SOF
Sponsor: Gilead Sciences
Recruiting - verified April 2016
Locations
Taiwan

__________________________________________________

Gilead Sciences
India
Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India
‎Thursday, ‎October ‎29, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C Virus
Intervention: Drug: SOF
Sponsor: Gilead Sciences
Recruiting - verified April 2016
India

__________________________________________________

Bristol-Myers Squibb
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
‎Thursday, ‎January ‎28, ‎2016, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: DCV; Drug: SOF; Drug: RBV
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2016


Locations
United States, California
Local Institution Not yet recruiting
Los Angeles, California, United States, 90033
Contact: Site 0011
U.Cal.-San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Norah Terrault, Site 0019
United States, Georgia
Gastrointestinal Specialists Of Georgia Pc Recruiting
Marietta, Georgia, United States, 30060
Contact: Aasim Sheikh, Site 0018
United States, Illinois
Ruth M. Rothstein Core Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Gregory Huhn, Site 0010
United States, Maryland
Digestive Disease Associates, P.A. Recruiting
Catonsville, Maryland, United States, 21228
Contact: Natarajan Ravendhran, Site 0014
United States, Pennsylvania
Eastern Pennsylvania Gastroenterology And Liver Specialists Recruiting
Allentown, Pennsylvania, United States, 18104
Contact: Adam Peyton, Site 0012
United States, Rhode Island
University Gastroenterology Recruiting
Providence, Rhode Island, United States, 02905
Contact: Thomas Sepe, Site 0017
United States, Texas
Texas Clinical Research Institute Recruiting
Arlington, Texas, United States, 76012
Contact: Reem Ghalib, Site 0009
Local Institution Not yet recruiting
Dallas, Texas, United States, 75203
Contact: Site 0020
Texas Liver Institute Recruiting
San Antonio, Texas, United States, 78215
Contact: Fred Poordad, Site 0013
United States, Virginia
Inova Fairfax Hospital Recruiting
Fairfax, Virginia, United States, 22046
Contact: James Cooper, Site 0008
Bon Secours St. Mary'S Hospital Of Richmond, Inc. Recruiting
Richmond, Virginia, United States, 23226
Contact: Mitchell Shiffman, Site 0016
Canada, Alberta
Local Institution Recruiting
Calgary, Alberta, Canada, T2N 4Z6
Contact: Site 0003
Canada, British Columbia
Local Institution Recruiting
Vancouver, British Columbia, Canada, V6Z 2K5
Contact: Site 0004
Local Institution Recruiting
Victoria, British Columbia, Canada, V8V 3P9
Contact: Site 0001
Canada, Ontario
Local Institution Recruiting
Toronto, Ontario, Canada, M5G 2C4
Contact: Site 0007
Canada, Quebec
Local Institution Not yet recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Site 0002
Canada
Local Institution Not yet recruiting
Regina Saskatchewan, Canada, S4O 0W5
Contact: Site 0006
Local Institution Not yet recruiting
Regina Saskatchewan, Canada, S4O 0W5
Contact: Site 0005
Japan

__________________________________________________

Bristol-Myers Squibb
Korea
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
‎Friday, ‎March ‎18, ‎2016, ‏‎12:00:00 PM
Condition: Hepatitis C
Intervention:
Sponsor: Bristol-Myers Squibb
Recruiting - verified April 2016
Locations
Korea, Republic of
Local Institution Recruiting
Seoul, Korea, Republic of
Contact: Site 0001

__________________________________________________

Merck Sharp & Dohme Corp
United States, Florida
A Study of the Pharmacokinetics of MK-3682 and MK-8408 in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
‎Monday, ‎January ‎25, ‎2016, ‏‎12:00:00 PM
Condition: Hepatitis C, Chronic
Interventions: Drug: MK-3682; Drug: MK-8408
Sponsor: Merck Sharp & Dohme Corp.
Recruiting - verified April 2016

Contacts
Contact: Toll Free Number 1-888-577-8839

Locations
United States, Florida
Call for Information (Investigational Site 0001) Recruiting
Hialeah, Florida, United States, 33014
Call for Information (Investigational Site 0002) Recruiting
Orlando, Florida, United States, 32809

__________________________________________________

Merck Sharp & Dohme Corp
United States, Florida
Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency
‎Tuesday, ‎January ‎19, ‎2016, ‏‎12:00:00 PM
Condition: Hepatitis C
Intervention: Drug: MK-3682B
Sponsor: Merck Sharp & Dohme Corp.
Recruiting - verified April 2016
Contacts

Contact: Toll Free Number 1-888-577-8839

Locations
United States, Florida
Call for Information (Investigational Site 0001) Recruiting
Hialeah, Florida, United States, 33014
Call for Information (Investigational Site 0002) Recruiting
Orlando, Florida, United States, 32809

__________________________________________________

Merck Sharp & Dohme Corp.
Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
‎Friday, ‎November ‎20, ‎2015, ‏‎12:00:00 PM
Conditions: Hepatitis; Hepatitis C; Digestive System Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Liver Diseases; RNA Virus Infections; Virus Diseases
Interventions: Drug: MK- 3682B; Drug: Ribavirin
Sponsor: Merck Sharp & Dohme Corp.
Recruiting - verified April 2016

Locations
United States, California
Call for Information (Investigational Site 0052) Recruiting
Coronado, California, United States, 92118
Call for Information (Investigational Site 0022) Recruiting
La Jolla, California, United States, 92037
Call for Information (Investigational Site 0044) Recruiting
Los Angeles, California, United States, 90036
Call for Information (Investigational Site 0029) Recruiting
San Diego, California, United States, 92103
Call for Information (Investigational Site 0047) Recruiting
San Diego, California, United States, 92154
United States, Colorado
Call for Information (Investigational Site 0008) Recruiting
Englewood, Colorado, United States, 80113
United States, Florida
Call for Information (Investigational Site 0016) Recruiting
Cooper City, Florida, United States, 33024
United States, Georgia
Call for Information (Investigational Site 0025) Recruiting
Atlanta, Georgia, United States, 30309
United States, Louisiana
Call for Information (Investigational Site 0001) Recruiting
New Orleans, Louisiana, United States, 70112
United States, Maryland
Call for Information (Investigational Site 0045) Recruiting
Baltimore, Maryland, United States, 21287-9106
United States, Missouri
Call for Information (Investigational Site 0035) Recruiting
St. Louis, Missouri, United States, 63104
United States, New Jersey
Call for Information (Investigational Site 0026) Recruiting
Egg Harbor, New Jersey, United States, 08234
Call for Information (Investigational Site 0019) Recruiting
Hillsborough, New Jersey, United States, 08844
United States, North Carolina
Call for Information (Investigational Site 0039) Recruiting
Chapel Hill, North Carolina, United States, 27599-7584
Call for Information (Investigational Site 0030) Recruiting
Charlotte, North Carolina, United States, 28204
United States, Pennsylvania
Call for Information (Investigational Site 0024) Recruiting
Hershey, Pennsylvania, United States, 17033
Call for Information (Investigational Site 0051) Recruiting
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Call for Information (Investigational Site 0004) Recruiting
Arlington, Texas, United States, 76012
Call for Information (Investigational Site 0014) Recruiting
Dallas, Texas, United States, 75203
Call for Information (Investigational Site 0028) Recruiting
Houston, Texas, United States, 77030
Call for Information (Investigational Site 0010) Recruiting
San Antonio, Texas, United States, 78215
France
MSD France Recruiting
Paris, France
Contact: Dominique Blazy 33 147548990
Germany
Merck Sharp & Dohme GmbH Recruiting
Haar, Germany
Contact: German Medical Information Center 49 800 673 673 673
Spain
Merck Sharp and Dohme de Espana S.A. Recruiting
Madrid, Spain
Contact: Joaquin Mateos Chacon (0034) 913210600
Sweden
MSD Sweden Recruiting
Stockholm, Sweden
Contact: Tryggve Ljung 46 (0)70 545 28 66

__________________________________________________

Merck Sharp & Dohme Corp
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
‎Tuesday, ‎January ‎6, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: Grazoprevir; Drug: MK-3682; Drug: MK-8742; Drug: MK-8408; Drug: MK-3682B; Drug: RBV
Sponsor: Merck Sharp & Dohme Corp.
Recruiting - verified April 2016

Locations
United States, California
Call for Information (Investigational Site 0042) Recruiting
Bakersfield, California, United States, 93301
Call for Information (Investigational Site 0010) Recruiting
Coronado, California, United States, 92118
Call for Information (Investigational Site 0046) Recruiting
San Diego, California, United States, 92154
Call for Information (Investigational Site 0004) Recruiting
San Diego, California, United States, 92123
Call for Information (Investigational Site 0047) Recruiting
San Marcos, California, United States, 92078
United States, Colorado
Call for Information (Investigational Site 0045) Recruiting
Englewood, Colorado, United States, 80113
Call for Information (Investigational Site 0044) Recruiting
Wheat Ridge, Colorado, United States, 80033
United States, Georgia
Call for Information (Investigational Site 0035) Recruiting
Marietta, Georgia, United States, 30060
United States, Illinois
Call for Information (Investigational Site 0030) Recruiting
Chicago, Illinois, United States, 60637
United States, Maryland
Call for Information (Investigational Site 0037) Recruiting
Baltimore, Maryland, United States, 21287-9106
United States, Missouri
Call for Information (Investigational Site 0049) Recruiting
St. Louis, Missouri, United States, 63104
United States, New Jersey
Call for Information (Investigational Site 0021) Recruiting
Hillsborough, New Jersey, United States, 08844
United States, New York
Call for Information (Investigational Site 0003) Recruiting
Binghamton, New York, United States, 13903
United States, North Carolina
Call for Information (Investigational Site 0040) Recruiting
Charlotte, North Carolina, United States, 28204
United States, Oklahoma
Call for Information (Investigational Site 0038) Recruiting
Tulsa, Oklahoma, United States, 74104
United States, Texas
Call for Information (Investigational Site 0048) Recruiting
Arlington, Texas, United States, 76012
Call for Information (Investigational Site 0015) Recruiting
Dallas, Texas, United States, 75390
Call for Information (Investigational Site 0019) Recruiting
Fort Worth, Texas, United States, 76104
Call for Information (Investigational Site 0039) Recruiting
Houston, Texas, United States, 77030
Call for Information (Investigational Site 0014) Recruiting
San Antonio, Texas, United States, 78215
United States, Virginia
Call for Information (Investigational Site 0043) Recruiting
Falls Church, Virginia, United States, 22042
Call for Information (Investigational Site 0036) Recruiting
Newport News, Virginia, United States, 23602
Canada, Quebec
Merck Canada Recruiting
Kirkland, Quebec, Canada, H9H 3L1
Contact: Medical Information Centre Centre de l'information medicale de Merck Canada 514-428-8600 / 1-800-567-2594
France
MSD France Recruiting
Paris, France
Contact: Dominique Blazy 33 147548990
Germany
Merck Sharp & Dohme GmbH Recruiting
Haar, Germany
Contact: German Medical Information Center 49 800 673 673 673
Israel
Merck Sharp & Dohme Co. Ltd. Recruiting
Hod Hasharon, Israel
Contact: Gally Teper 972-9-9533310
Italy
MSD Italia S.r.l. Recruiting
Rome, Italy
ct: Patrizia Nardini 39 06 361911
New Zealand
Merck Sharp & Dohme (New Zealand) Ltd., Recruiting
Wellington, New Zealand
Contact: Australian Medical Information Centre 61 2 8988 8428